|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-5-18
|
|
pubmed:abstractText |
Temozolomide is an oral alkylating agent that crosses the blood-brain barrier, and has preclinical activity in breast cancer. This phase II trial sought to determine the activity and toxicity of temozolomide in metastatic breast cancer (MBC). Temozolomide was administered in a dose dense schedule of 150 mg/m(2) on days 1-7 and 15-21 in a 28-day cycle.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
952-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16565212-Administration, Oral,
pubmed-meshheading:16565212-Adult,
pubmed-meshheading:16565212-Aged,
pubmed-meshheading:16565212-Antineoplastic Agents, Alkylating,
pubmed-meshheading:16565212-Breast Neoplasms,
pubmed-meshheading:16565212-Dacarbazine,
pubmed-meshheading:16565212-Disease Progression,
pubmed-meshheading:16565212-Drug Administration Schedule,
pubmed-meshheading:16565212-Female,
pubmed-meshheading:16565212-Humans,
pubmed-meshheading:16565212-Middle Aged,
pubmed-meshheading:16565212-Neoplasm Metastasis,
pubmed-meshheading:16565212-Patient Selection,
pubmed-meshheading:16565212-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).
|
|
pubmed:affiliation |
Toronto Sunnybrook Regional Cancer Centre, ON, Canada. Maureen.Trudeau@sw.ca
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
